美康生物携手北大一院获批国家重大专项 VAP精准血脂检测技术助力破解心脑血管残余风险

Group 1 - The core project "Research on Lipoprotein Profile and New Intervention Targets Based on Large Natural Population Cohorts" has been officially approved, aiming to address residual risk in atherosclerotic cardiovascular diseases using VAP precision lipid testing technology [1] - VAP precision lipid testing technology utilizes vertical density gradient centrifugation to quantitatively measure major components and subcomponents of lipoproteins in human serum or plasma, providing significant value in risk prediction and individualized treatment for cardiovascular diseases [1] - The company has obtained Class II medical device registration for VAP-related reagents and instruments, and its testing methods have been included in national clinical guidelines, enhancing market recognition and clinical application of precision lipid products [1] Group 2 - The company has over 20 years of experience in the IVD industry, with a comprehensive product line covering various technology platforms, making it one of the most complete and diverse IVD manufacturers in China [2] - The strategic layout of the company focuses on the synergy of diagnostic instruments, core diagnostic products, and diagnostic services, supported by multiple R&D centers and collaborations with universities and research institutions [2] - As of the end of 2024, the company has obtained 49 diagnostic instrument registration certificates and 459 supporting reagent registration certificates, covering essential equipment for various diagnostic needs [2] Group 3 - The company is the first Chinese IVD manufacturer to join JCTLM, promoting standardization and global recognition of test results, and has participated in the development of over 30 international and national standard materials [3] - The collaboration with Peking University First Hospital on the national major science and technology project signifies a breakthrough in the integration of industry, academia, and research [3] - The company plans to increase R&D investment and deepen technological innovation, aiming to contribute to chronic disease management and prevention in alignment with the "Healthy China 2030" strategy [3]